US-based biotechnology company Ocugen has dosed the first subject in a multicentre Phase I trial of OCU200 for diabetic ...

Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and ...

Shares of Ocugen Inc. OCGN slid 1.91% to $0.72 Thursday, on what proved to be an all-around rough trading session for the ...

Ocugen (OCGN) announced that the first patient has been dosed in the OCU200 Phase 1 clinical trial for diabetic macular edema, DME. “OCU200 has ...

On Thursday, Ocugen Inc (OCGN) stock saw a decline, ending the day at $0.71 which represents a decrease of $-0.02 or -2.74% from the prior close of $0.73. The stock opened at $0.74 and touched a low ...

MALVERN, Pa., Jan. 16, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering ...

Ocugen, Inc. has announced the commencement of its Phase 1 clinical trial for OCU200, targeting diabetic macular edema (DME). The trial, which has begun dosing its first patient, aims to evaluate ...

On Tuesday, Ocugen Inc (OCGN) stock saw a decline, ending the day at $0.73 which represents a decrease of $-0.02 or -2.67% from the prior close of $0.75. The stock opened at $0.75 and touched a low of ...

MALVERN, Pa., Jan. 16, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a ...

Ocugen, Inc. announced positive results from its Phase 1/2 clinical trial of OCU400, a novel gene therapy aimed at treating retinitis pigmentosa (RP). The study showed that 100% of treated ...